54 results about "Molecular vector" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides for the treatment of a disease or condition (e.g., a disease or disorder) using an agent comprising and / or modulating the expression or activity of an immunomodulatory-related protein. The present invention relates to methods for identifying such agents (e.g., diseases or conditions associated with whole genome association studies (GWAS), cancer genome maps (TCGA), whole genome sequencing, whole phenotype group association studies (PheWAS), expression quantitative trait locus (eQTL) studies, or combinations thereof), and methods for identifying such agents.

The invention relates to a preparation method of a p-cresol sulfate (PCS) detection kit by using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a p-cresol sulfate (PCS) detection kit. P-cresol sulfate is a protein-bound uremic toxin in a human body, has small molecular weight and poor immunogenicity, and when a corresponding antibody is prepared, a hapten and a specific macromolecular carrier need to be coupled to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a sulfuric acid p-cresol hapten, preparation of a sulfuric acid p-cresol complete antigen and an anti-sulfuric acid p-cresol antibody, a method for measuring the concentration of sulfuric acid p-cresol, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a sulfuric acid p-cresol derivative. The p-cresol sulfate derivative disclosed by the invention has a structure as shown in a formula (I): # imgabs0 #, wherein R is-(CH2) n-COOH, and n is 4.

The invention provides a molecular characterization model training method, a molecular characterization model retrieval method and a molecular characterization model retrieval device, which are applied to the technical field of artificial intelligence. The model training method comprises the following steps: acquiring a training sample set which comprises a molecular character string sample and a molecular text description sample; performing feature coding on the molecular character string sample through an encoder to obtain a first molecular vector representation of the molecular character string sample, and performing feature coding on the molecular text description sample to obtain a first text vector representation of the molecular text description sample; aggregating the first molecular vector representation into at least one first molecular feature class by utilizing a clustering algorithm, and aggregating the first text vector representation into at least one first text feature class by utilizing the clustering algorithm; obtaining a first loss function according to the at least one first molecular feature class and the at least one first text feature class; and according to the first loss function, updating parameters of the encoder to obtain the molecular characterization model. Therefore, the accuracy of chemical analysis and interpretation of molecules can be improved.

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and / or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and / or protein replacement, or a combination thereof using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.

This platform is a privacy-preserving, federated learning system designed to integrate whole-slide digital pathology images with matched molecular profiling and clinical metadata for improved diagnosis, subtyping, and prognostic estimation of gynecologic tumors. The architecture comprises local institutional nodes that retain raw patient data while participating in distributed model training coordinated by a central orchestration server. Each local node preprocesses whole-slide images into patch-level tensors, extracts visual embeddings via convolutional backbones, and processes molecular vectors (e.g., somatic mutations, expression summaries, copy-number measures) via a molecular encoder. A multimodal fusion module - implemented as an attention- based transformer - integrates image and molecular embeddings into a unified representation used by multi-task heads for classification (histologic subtype, diagnostic label) and regression (risk score). The federated learning controller aggregates encrypted model updates (FedAvg) and returns improved global weights without exchanging raw data, enabling cross-site generalization while preserving patient privacy. Explainability components generate attention maps and tile-level saliency (Grad-CAM style) linked to molecular features, providing interpretable morpho- molecular correlations to pathologists. The platform supports API integration with PACS / LIMS, conforms to privacy standards via optional differential privacy and secure aggregation layers, and is extensible to additional omics modalities or transfer / fine-tuning workflows for related tumor types. By combining multimodal fusion, federated training, and clinician-facing interpretability, the system accelerates robust, generalizable AI for precision pathology in gynecologic oncology.

Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and / or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.

The application relates to the technical field of molecular property prediction and digital medical treatment, and discloses a molecular property prediction model training method, a storage medium, a computer device and a molecular property prediction device. The method comprises the following steps: acquiring molecular graphs of a plurality of sample molecules, splitting the molecular graphs to obtain candidate graph prompts, extracting a preset number of candidate graph prompts as target graph prompts according to a preset candidate graph prompt extraction rule; encoding the target graph prompts into target graph prompt vectors, calculating the importance weights of the target graph prompt vectors on the molecular graphs, calculating a global graph prompt vector according to the target graph prompt vectors and the importance weights; splicing the global graph prompt vector with feature vectors of the sample molecules respectively to obtain molecular vectors of the sample molecules; and training a molecular property prediction model according to preset molecular property labels corresponding to the sample molecules and the molecular vectors. The trained model can simultaneously predict a plurality of molecular properties, and the drug research and development efficiency is improved.

The present invention discloses a 3'UTR for improving mRNA translation efficiency and its application, belonging to the field of biotechnology. The present invention provides a 3'UTR sequence for regulating mRNA translation efficiency, a corresponding DNA molecule, a vector, a host cell, and an RNA molecule. The present invention also provides a method for improving mRNA translation efficiency and related applications. The 3'UTR sequence provided by the present invention can significantly improve the expression efficiency of mRNA. Regardless of whether the base is modified or unmodified, the improved mRNA translation efficiency is 2-3 times that of a commonly used 3'UTR sequence.

The present invention provides, in part, a protein-drug conjugate comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., a polynucleotide, a polypeptide, a liposome, or a lipid nanoparticle), for delivering the molecular cargo to a target tissue (e.g., the brain). Methods are provided for treating various diseases or disorders, such as neurological disorders, with the conjugate.

The present disclosure provides compositions such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells that include and / or modulate the expression or activity of immunoregulatory-related proteins in various embodiments. The present disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infectious diseases, and / or immune disorders using agents that include and / or modulate the expression or activity of immunoregulatory-related proteins, as well as methods of identifying said agents.

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and / or modulate expression or activity of immune regulation-associated proteins, such as cytokines. The disclosure also provides, in various embodiments, methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, an infection, and / or an immunological disease using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein, and methods of identifying said agent.

Provided are a phytase mutant and a coding DNA molecule thereof, a vector, and a host cell. The phytase mutant comprises an amino acid sequence having at least 90% identity with SEQ ID NO: 3, and compared with SEQ ID NO: 3, and contains an amino acid substitution at at least one position selected from the group consisting of 36, 126, 211, 253, 258, and 266. The heat resistance of the mutant is significantly improved, thus facilitating the wide application of phytase in feed.

The application discloses a plant-expressed varicella-zoster virus gB recombinant antigen and a preparation method, product and application thereof, and belongs to the technical field of plant molecular biology and vaccine engineering. The technical problems to be solved are that the existing VZV gB protein has low heterologous expression, poor stability and insufficient antigen activity; the existing VZV vaccine has high production cost, is difficult to popularize and has a single antigen with an immune escape risk; and the plant expression system is not mature in VZV gB antigen production, and lacks a complete preparation scheme and related products. The technical solution is that the natural VZV gB protein is modified, a furin protease cleavage site is knocked out, and a H527P mutation is introduced, related nucleic acid molecules, vectors and plant source cells are constructed, high-activity antigens are obtained through culture and purification, and the high-activity antigens are applied to the preparation of VZV drugs / vaccines, and have the advantages of low cost, high safety and strong immunogenicity.

The invention relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit. Endophalin is also called as brain endophine, is a morphine-like biochemical synthetic hormone and is secreted by pituitary gland. Beta-enorphin is small in molecular weight and poor in immunogenicity and has various structural analogues, so that when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to the design and synthesis of a beta-enorphin hapten, the preparation of a beta-enorphin complete antigen and an anti-beta-enorphin antibody, a method for measuring the concentration of beta-enorphin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a beta-ennorphin derivative. The beta-ennorphin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and / or modulate expression or activity of immune regulation-associated proteins, such as cytokines. The disclosure also provides, in various embodiments, methods of treating a disease or condition (e.g., a disease or condition associated with the Genome-Wide Association Study (GWAS), the Cancer Genome Atlas (TCGA), whole genome sequencing, phenome-wide association study (PheWAS), expression quantitative trait locus (cQTL) studies, or a combination thereof) using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein, and methods of identifying said agent.

The invention relates to preparation of a xanthine (Xanthine) detection kit by using a chemiluminescence immunoassay technology. Xanthine is purine widely existing in body fluid, tissues and plant cells and is small in molecular weight and poor in immunogenicity, and when a corresponding antibody is prepared, a hapten needs to be coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a xanthine hapten, preparation of a xanthine complete antigen and an anti-xanthine antibody, a method for measuring the concentration of xanthine, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise the design and chemical synthesis of xanthine derivatives. The xanthine derivative disclosed by the invention has a structure as shown in a formula (I): # imgabs0 #, wherein R is-(CH2) n-COOH, and n is any integer between 1 and 10.

This application belongs to the field of immunoassay technology, specifically relating to specific binding proteins of hepatitis B viruses (MHBs), nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides a specific binding protein of MHBs with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with large and small proteins, thus improving detection specificity and avoiding false positive results. The specific binding protein of MHBs in this application can bind to a chemiluminescent detection system, thereby achieving highly sensitive detection of MHB antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

This application belongs to the field of immunoassay technology, specifically relating to LHBs-specific binding proteins, nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides an LHBs-specific binding protein with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with medium and small proteins, thus improving detection specificity and avoiding false positive results. The LHBs-specific binding protein of this application can bind to chemiluminescent detection systems, thereby achieving highly sensitive detection of LHBs antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

The present invention relates to the technical field of biology, in particular to a phytase mutant, a preparation method therefor and an application thereof, a DNA molecule encoding the phytase mutant, a vector, and a host cell. The mutant provided by the present invention contains the substituent of an amino acid at at least one position selected from the following group: 36, 69, 89, 91, 111, 202, 213, 225, 238, 243, 253, 258, and 266. The heat resistance of the mutant is significantly improved, thereby facilitating the wide application of the phytase in feed.

The invention discloses a compound fat solubility prediction method based on a multilevel feature fusion graph neural network, and relates to the field of computational pharmacology and chemical information.The method comprises the steps that an atomic-scale graph structure, molecular-scale global features and group-scale substructure features of a target molecular compound are obtained; performing feature extraction on the atomic-scale graph structure to obtain an embedded representation of each atom in the target molecular compound, and performing global average pooling on the embedded representation of each atom to obtain an atomic vector; normalizing the molecular-level global features to form molecular vectors; splicing the atom vector, the molecule vector and the substructure vector to obtain a global vector; predicting the fat solubility of the target molecular compound according to the global vector; according to the method, an atom-molecule-substructure multilevel characteristic system is constructed, and the characteristics with different granularities and different properties are organically combined for combined prediction, so that more comprehensive molecular characterization and more accurate fat solubility prediction of molecular compounds are realized.

The invention discloses a guide RNA (Ribonucleic Acid) molecule, a vector and application of the guide RNA molecule and the vector in a medicine for preventing and treating ATTR (Attenuated Transporter Receptor), and relates to the technical field of gene therapy. The guide RNA is set according to the coding sequence of the TTR gene, the guide RNA for gene editing is screened, it is found that the sequence similar to the guide sequence of the guide RNA has high TTR gene editing efficiency, the expression level of TTR in the liver of an experimental mouse and the level of TTR in blood circulation can be effectively reduced by constructing a gene editing carrier, and the TTR gene editing efficiency is improved. And the deposition of TTR between important organs and tissues can be effectively improved. Therefore, the guide RNA provided by the invention has a good application prospect in prevention and / or treatment of ATTR.

The invention discloses a knee joint targeting stem cell exosome composition as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The composition comprises a core-shell structure consisting of a stem cell exosome and a targeting stabilized functional macromolecule coating the surface of the stem cell exosome, the targeting stabilizing functional macromolecule is formed by connecting a biocompatible polysaccharide skeleton, a membrane anchoring hydrophobic group and a knee joint focus targeting ligand through covalent bonds. Through integrated molecular design, a stabilizing function and a targeting function are integrated on the same macromolecular carrier, and the macromolecular carrier is worn on the surface of the exosome through a self-assembly technology, so that the technical contradiction that stability and targeting cannot be achieved at the same time in an existing stem cell exosome technology is solved.

The present disclosure provides compositions such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells that include and / or modulate the expression or activity of immunoregulatory-related proteins in various embodiments. The present disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infectious diseases, immune diseases, hormones, growth factors, and / or indications treated with protein replacement, or combinations thereof, using agents that include and / or modulate the expression or activity of immunoregulatory-related proteins, as well as methods of identifying such agents.

The application discloses a kind of knee joint targeting stem cell exosome compositions and preparation method and application thereof, it is related to biological medicine technical field.The composition includes the core-shell structure that is made of stem cell exosome and the targeting stable functional macromolecule that is coated on the surface of stem cell exosome;The targeting stable functional macromolecule is made of biocompatible polysaccharide skeleton, membrane anchoring hydrophobic group and knee joint lesion targeting ligand by covalent bond connection composition.The application is integrated in the same macromolecule carrier by integrated molecular design, and by self-assembly technology, it is " dressed " on the surface of exosome, solves the technical contradiction that stability and targeting cannot be obtained in existing stem cell exosome technology.

Short hairpin RNA (shRNA) molecules that target human endogenous retrovirus K (HERV-K) nucleic acid, as well as vectors containing the coding sequences for the shRNA molecules, are described. In some instances, the vector containing the shRNA coding sequences is an adeno-associated virus (AAV) vector, such as a self-complementary AAV vector. Use of the shRNA molecules, vectors and compositions thereof for the treatment of neurological disorders, such as motor neuron diseases, and cancer is also described.

The present disclosure provides compositions such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells that include and / or modulate the expression or activity of immune regulatory related proteins such as cytokines in various embodiments. The present disclosure also provides methods for treating a disease or condition (e.g., a disease or condition related to genome-wide association studies (GWAS), The Cancer Genome Atlas (TCGA), whole genome sequencing, phenome-wide association studies (PheWAS), expression quantitative trait locus (eQTL) studies, or a combination thereof) using an agent that includes and / or modulates the expression or activity of an immune regulatory related protein, as well as methods for identifying said agent.

The application discloses a compound liposolubility prediction method based on a multi-level feature fusion graph neural network, relates to the field of computational pharmacology and chemical informatics, and comprises the following steps: acquiring an atomic-level graph structure, a molecular-level global feature and a group-level substructure feature of a target molecular compound; performing feature extraction on the atomic-level graph structure to obtain an embedding representation of each atom in the target molecular compound, and performing global average pooling on the embedding representation of each atom to obtain an atomic vector; performing normalization on the molecular-level global feature to form a molecular vector; splicing the atomic vector, the molecular vector and a substructure vector to obtain a global vector; predicting the liposolubility of the target molecular compound according to the global vector; and constructing a multi-level feature system of 'atoms-molecules-substructures', and combining the features with different granularities and different properties organically to perform joint prediction, so that more comprehensive molecular representation and more accurate liposolubility prediction of the molecular compound are realized.

The invention relates to the technical field of artificial intelligence data security, in particular to a method and system for providing data protection for a model reasoning sample, and a storage medium, and the method comprises the steps: receiving multi-modal sample data, and converting the multi-modal sample data into a standard format; pseudo sample data is generated through a hybrid generation framework, and it is ensured that the chemical structure and model input sample data are the same in type and reasonable; verifying the mixed model input sample data and pseudo sample data to ensure that the pseudo sample data conceals the characteristics of the model input sample data; and a task scheduling mechanism is used to enhance data privacy protection. In addition, through molecular vector representation, dimension reduction visualization and public database comparison, the performance of a mixed sample in a vector space is verified, it is ensured that model input sample data cannot be leaked, sensitive data leakage is effectively avoided, and meanwhile the accuracy of a reasoning result is ensured.